Executive Vice President, UPMC Enterprises
Jeanne has more than two decades of experience as a life science venture capital investor and advisor. Leveraging the multifaceted resources of UPMC, a $20 billion world-renowned health care provider and insurer, Jeanne leads investments related to UPMC’s $200 million initial commitment to invest in innovative therapies and diagnostic products. Jeanne’s team collaborates closely with scientist-entrepreneurs to invest in creation of new companies, as well as in building companies at all stages, with a focus on immunotherapy for cancer, transplantation, diseases related to aging and other chronic illnesses.
Jeanne serves on the boards of three UPMC Enterprises portfolio companies, BlueSphere Bio, Generian, and Humonic, Inc., and is a member of the executive committee of the UPMC Genome Center. Prior to joining UPMC, she was a Managing Director and Investment Partner at Bay City Capital, where she focused on medical device, drug delivery, and drug development companies. She has served on the Boards of Directors of IDev Technologies, Protez Pharmaceuticals, NuPathe, Inc., and Calypso Medical, and as a board observer for Oculex and Syntonix Pharmaceuticals. Previously, she managed the Ernst & Young International Life Sciences Group’s industry-leading annual biotechnology report.
Jeanne is a member of the Board of Trustees of Carnegie Mellon University, serving on the executive, compensation, advancement, and audit committees. She received an MBA in Finance from the University of San Francisco and holds a BA in Cognitive Psychology from Carnegie Mellon University.